Athersys (NASDAQ:ATHX) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Athersys (NASDAQ:ATHXGet Free Report) in a note issued to investors on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Athersys has a one year low of $0.01 and a one year high of $1.99. The stock has a market capitalization of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90.

About Athersys

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Read More

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.